Apyx Medical (NASDAQ:APYX) Stock Price Down 1.8% – What’s Next?

Posted by Geri Gentry on Jul 12th, 2026

Apyx Medical Corporation (NASDAQ:APYX – Get Free Report) shares were down 1.8% on Friday . The stock traded as low as $4.34 and last traded at $4.38. Approximately 43,859 shares traded hands during mid-day trading, a decline of 60% from the average daily volume of 109,807 shares. The stock had previously closed at $4.46.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Apyx Medical in a research note on Wednesday, June 24th. Wall Street Zen lowered Apyx Medical from a “buy” rating to a “hold” rating in a research note on Sunday, April 26th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $6.50.

View Our Latest Analysis on Apyx Medical

Apyx Medical Stock Performance

The stock’s fifty day moving average is $4.14 and its two-hundred day moving average is $3.88. The firm has a market capitalization of $183.57 million, a price-to-earnings ratio of -19.91 and a beta of 1.37. The company has a debt-to-equity ratio of 2.68, a quick ratio of 4.79 and a current ratio of 5.80.

Apyx Medical (NASDAQ:APYX – Get Free Report) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.05) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.06. The company had revenue of $12.49 million during the quarter, compared to analysts’ expectations of $10.53 million. Apyx Medical had a negative net margin of 16.40% and a negative return on equity of 88.47%.

Hedge Funds Weigh In On Apyx Medical

A number of institutional investors have recently made changes to their positions in the business. Nwam LLC acquired a new stake in shares of Apyx Medical during the first quarter worth approximately $47,000. Citadel Advisors LLC bought a new position in Apyx Medical during the 3rd quarter valued at $28,000. Hudson Bay Capital Management LP acquired a new position in Apyx Medical during the 4th quarter worth $73,000. Osaic Holdings Inc. bought a new stake in shares of Apyx Medical in the 2nd quarter worth about $50,000. Finally, Franklin Resources Inc. bought a new stake in shares of Apyx Medical in the 3rd quarter worth about $59,000. 55.33% of the stock is owned by institutional investors and hedge funds.

Apyx Medical Company Profile

(Get Free Report)

Apyx Medical (NASDAQ: APYX) is a medical device company focused on the development and commercialization of energy-based solutions for surgical and aesthetic applications. The company’s product portfolio includes devices that utilize radiofrequency energy, cold plasma and proprietary technologies designed to deliver precise thermal control and tissue treatment. Its key offerings encompass the J-Plasma technology under the Renuvion brand, which is primarily used for subdermal skin tightening and aesthetic procedures, and its portfolio of advanced energy medical devices for general surgery, gynecology and dermatology.

Leveraging its dual focus on surgical and aesthetic markets, Apyx Medical serves physicians and healthcare providers across North America, Europe and select international regions.